Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

After two years of steady gains, the stock market is now experiencing one of its sharpest corrections in recent history. US ...

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are ...

We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look ...

Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...

Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.

Recursion is currently generating limited revenue through partnerships with larger pharmaceutical leaders like Merck and ...

The Merck Foundation, partnered with African First Ladies, is enhancing women's empowerment in underserved communities.

What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...